Diligence memo · auto-generated · as of July 2, 2026
Avivomed Inc.
Avivomed Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Avivomed Inc. operates in Biotechnology, based in MINNEAPOLIS.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Avivomed Inc. has raised $20M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $20M on 2021-11-03.
Most recent recorded round closed around 2021-11-03.
Valuation (modeled)modeled
Provath models Avivomed Inc. at approximately $449M (range $40M–$1.3B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.73× the median modeled value of Series B Biotechnology companies in 2019–2021 (118 peers) — value vs value, same stage and era. Within the normal band (73% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 4.7 yr ago; this sector typically re-raises about every 14 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 68% of Biotechnology peers (4293 compared).
Modeled value ranks above 82% of those peers.
Closest niche peers: Pandion Therapeutics Holdco LLC, Ocular Therapeutix, Inc, Insilico Medicine Cayman TopCo, Purigen Biosystems, Inc., Lucira Health, Inc..
Peoplefiled
6 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.